Product Information
MITIGARE 0.6 MG CAPSULE is a brand product labeled by Hikma Specialty USA Inc., priced at $6.0293 per EA under NDC 59467031810. Its NADAC has been published 546 times since Apr 20, 2016.
FDA first approved this application on Sep 26, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Colchicine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.6 mg/1
Manufacturer
Hikma Specialty USA Inc.NDC
59467031810
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
COLCHICINEApproval Type
New Drug (NDA)
FDA Application
NDA204820FDA Approved
9/26/2014
TE Code
AB
On Market Since
10/1/2014
Pharmacological Classes
Price Statistics
The NADAC for MITIGARE 0.6 MG CAPSULE has been published 546 times since Apr 20, 2016, and over the history we have for it it has risen 8.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.0293 per EA |
|---|---|
| All-time high | $6.0603 (Jun 14, 2023) |
| All-time low | $5.4862 (Jan 18, 2017) |
| 52-week high | $6.0434 |
| 52-week low | $6.0077 |
| Median price | $6.0196 |
| Average price | $5.8771 |
| Largest weekly change | +5.5% (Feb 10, 2021) |
| Weeks tracked | 546 |
| Tracking since | Apr 20, 2016 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 71% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Specialty USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Colchicine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Alkaloid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MITIGARE 0.6 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MITIGARE 0.6 MG CAPSULE, manufactured by Hikma Specialty USA Inc., is $6.0293 per EA (NDC 59467031810), effective Sep 30, 2026.
How has the price of MITIGARE 0.6 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MITIGARE 0.6 MG CAPSULE has risen 8.8%. It has been tracked across 546 weekly CMS publications since Apr 20, 2016.
What are the highest and lowest recorded NADAC prices for MITIGARE 0.6 MG CAPSULE?
Since Apr 20, 2016, the NADAC for MITIGARE 0.6 MG CAPSULE has ranged from a low of $5.4862 (Jan 18, 2017) to a high of $6.0603 (Jun 14, 2023), with a median of $6.0196 per EA.
Are there cheaper alternatives to MITIGARE 0.6 MG CAPSULE?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, COLCHICINE 0.6 MG CAPSULE, is $1.7528 per EA — about 71% below MITIGARE 0.6 MG CAPSULE.
Who manufactures MITIGARE 0.6 MG CAPSULE?
MITIGARE 0.6 MG CAPSULE (NDC 59467031810) is labeled by Hikma Specialty USA Inc., and CMS classifies it as a brand product.